State Key Laboratory of Materials-Oriented Chemical Engineering, College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211800, P.R. China.
Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, P.R. China.
Curr Pharm Des. 2024;30(6):448-467. doi: 10.2174/0113816128287155240122121553.
Chuang-Ling-Ye (CLY) has been clinically proven to be an effective Chinese medicine for the treatment of diabetic foot ulcers (DFU).
This study aimed to investigate the possible mechanism of CLY in relation to DFU using network pharmacology and molecular docking.
Firstly, relevant targets of CLY against DFU were obtained from TCMSP, Swiss Target Prediction database and GEO database. Then, topological analysis was employed by Cytoscape to screen the top 6 core active ingredients and the top 8 hub targets. Furthermore, the OmicShare Tools were applied for gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis. Finally, the results of network pharmacology were verified by molecular docking method.
CLY has 61 active compounds and 361 targets after de-duplication, and the top 8 hub targets were EGFR, TP53, CCND1, IL-1B, CREBBP, AR, PTGS2 and PGR. GO enrichment analysis is mainly related to signal transducer activity, receptor activity, and molecular transducer activity. KEGG pathway analysis indicated that these shared targets were primarily focused on AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, IL-17 signaling pathway, and JAK-STAT signaling pathway. Molecular docking results showed that physciondiglucoside, 2-cinnamoyl-glucose and kinobeon A were well bound with EGFR, IL-1B, AR and PTGS2.
This study demonstrated that CLY has anti-oxidative stress and anti-inflammatory effects in the treatment of DFU through various constituents, multiple targets, and multiple pathways, which provides a valuable point of reference for future investigations on CLY.
临床研究已证实疮灵液是一种治疗糖尿病足溃疡(DFU)的有效中药。
本研究旨在采用网络药理学和分子对接的方法探讨疮灵液治疗 DFU 的作用机制。
首先,从 TCMSP、Swiss Target Prediction 数据库和 GEO 数据库中获取疮灵液治疗 DFU 的相关靶点。然后,采用 Cytoscape 进行拓扑分析,筛选出前 6 个核心活性成分和前 8 个关键靶点。进一步采用在线数据库 OmicShare Tools 进行基因本体(GO)功能富集分析和京都基因与基因组百科全书(KEGG)信号通路富集分析。最后,采用分子对接方法验证网络药理学的结果。
经去重后,疮灵液共有 61 个活性成分和 361 个作用靶点,前 8 个关键靶点分别为表皮生长因子受体(EGFR)、TP53、细胞周期蛋白 D1(CCND1)、白细胞介素 1β(IL-1β)、CREB 结合蛋白(CREBBP)、雄激素受体(AR)、前列腺素 G/H 合酶 2(PTGS2)和孕激素受体(PGR)。GO 富集分析主要与信号转导活性、受体活性和分子转导活性相关。KEGG 通路分析表明,这些共同靶点主要集中在糖尿病并发症的 AGE-RAGE 信号通路、缺氧诱导因子 1(HIF-1)信号通路、白细胞介素 17(IL-17)信号通路和 JAK-STAT 信号通路。分子对接结果显示,大黄素-8-O-β-D-葡萄糖苷、2-肉桂酰基葡萄糖和金诺柏 A 与 EGFR、IL-1B、AR 和 PTGS2 结合良好。
本研究表明,疮灵液通过多种成分、多个靶点和多条通路发挥抗氧化应激和抗炎作用,从而治疗 DFU,为今后进一步研究疮灵液提供了有价值的参考。